Optometry 360
  • Home
  • Conferences
  • Videos
  • About Us
    • About Us – Mission
    • Media Partners
    • Advisory Board
    • Industry Council
    • Business Team

What are you looking for?

  • Conference Roundup
  • Contact Lenses
  • Diagnostics
  • Glaucoma
  • Myopia
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Retina
  • Spotlight Series
Navigating Presbyopia Conversations with Patients in Practice
Optometry 360
  • Home
  • Conferences
  • Videos
  • About Us
    • About Us – Mission
    • Media Partners
    • Advisory Board
    • Industry Council
    • Business Team
Home > Study challenges the notion of ‘responders’ and ‘non-responders’ in myopia control
  • Myopia

Study challenges the notion of ‘responders’ and ‘non-responders’ in myopia control

Kelsey Moroz

The labels ‘responders’ and ‘non-responders’ in myopia control treatments are not supported by evidence, according to a study that found both fast and slow progressors experienced similar reductions in myopia progression and axial elongation when treated with low concentrations of atropine.

A recent analysis of data from participants in the Low-concentration Atropine for Myopia Progression (LAMP) study, a placebo-controlled trial that investigated the efficacy of 3 low concentrations of atropine in managing myopia over the first year, assessed the efficacy of atropine treatments by comparing the absolute reductions in myopia progression and axial elongation across different age groups and atropine concentrations.

Researchers found that the reduction in myopia progression and axial elongation was consistent across patients, regardless of whether they were initially fast or slow progressors. This suggests that the terms ‘responders’ and ‘non-responders’ may be misleading, as all participants experienced similar benefits from the treatment.

Reference
Brennan NA, Nixon AD, Cheng X, Bullimore MA. Can we really distinguish ‘responders’ from ‘non-responders’ to myopia control interventions? Ophthalmic Physiol Opt. 2024;doi: 10.1111/opo.13379. Epub ahead of print. PMID: 39229644.

Share

Related Content

  • Myopia

Low-dose atropine may reduce visual discomfort in adolescents with myopia

  • Pediatrics

Computer vision syndrome similar among students using digital and printed textbooks

  • Myopia

Demographic and clinical factors linked to low-dose atropine treatment in children

  • Myopia

Theialife plans Phase 3 trials of oral ND10 for progressive pediatric myopia

  • Myopia

High-dose atropine plus dual-focus lenses show minimal myopia progression

  • Myopia

Myopia Action Month: empowering practices to take the next step in myopia management

Share

Advisory Board

Kaleb Abbott, OD, MS, FAAO

Clark Chang, OD

Jessica Haynes, OD, FAAO, FORS, Dipl ABO

Monica Kalia, OD

Cecelia Koetting, OD, FAAO, DipABO

Roya Attar, OD, MBA, DHA, FAAO

Hardeep Kataria, OD, FAAO

Marc R. Bloomenstein, OD, FAAO

Elise Kramer, OD

See All
Optometry 360

Optometry 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

© 2026 Optometry 360 is a trademark of International Healthcare Media, LLC. All rights Reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophthalmology360 Icon